Mirum Pharmaceuticals (MIRM) Return on Capital Employed (2019 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Return on Capital Employed of 134.07% for Q1 2026, down 12026.0% year-over-year from N/an in Q1 2025, and down 3583.39% quarter-over-quarter from 3.64% in Q4 2025.
Mirum Pharmaceuticals (MIRM) Return on Capital Employed (2019 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 134.07% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 12026.0% year-over-year to 134.07%; the TTM figure through Mar 2026 stood at 134.07% (down 12026.0% YoY), while the FY2025 annual figure was 4.02%, up 1245.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 134.07%, down from 3.64% in the prior quarter.
- The five-year high for Return on Capital Employed was 3.64% in Q4 2025, with the low at 134.07% in Q1 2026.
- The 5-year median for Return on Capital Employed is 19.96% (2024), against an average of 34.42%.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed jumped 3521 bps in 2022, then plunged 12026 bps in 2026.
- Mirum Pharmaceuticals' Return on Capital Employed stood at 44.65% in 2022, then soared by 56 bps to 19.44% in 2023, then advanced by 17 bps to 16.14% in 2024, then jumped by 77 bps to 3.64% in 2025, then sank by 3583 bps to 134.07% in 2026.
- Business Quant data shows MIRM's Return on Capital Employed at 134.07% in Q1 2026, 3.64% in Q4 2025, and 7.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | -111.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -111.92% |
| Mar 31, 2026 | -134.07% |
| Dec 31, 2025 | -3.64% |
| Sep 30, 2025 | -7.02% |
| Jun 30, 2025 | -10.13% |
| Mar 31, 2025 | -13.80% |
| Dec 31, 2024 | -16.14% |
| Sep 30, 2024 | -17.49% |
| Jun 30, 2024 | -19.93% |
| Mar 31, 2024 | -19.96% |
| Dec 31, 2023 | -19.44% |
| Sep 30, 2023 | -23.44% |
| Jun 30, 2023 | -35.86% |
| Mar 31, 2023 | -42.68% |
| Dec 31, 2022 | -44.65% |
| Sep 30, 2022 | -51.05% |
| Jun 30, 2022 | -62.91% |
| Mar 31, 2022 | -62.95% |
| Dec 31, 2021 | -78.00% |
| Sep 30, 2021 | -86.26% |